NO148777B - ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE ANTHRAKINON DERIVATIVES - Google Patents
ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE ANTHRAKINON DERIVATIVESInfo
- Publication number
- NO148777B NO148777B NO782756A NO782756A NO148777B NO 148777 B NO148777 B NO 148777B NO 782756 A NO782756 A NO 782756A NO 782756 A NO782756 A NO 782756A NO 148777 B NO148777 B NO 148777B
- Authority
- NO
- Norway
- Prior art keywords
- container
- piston
- syringe
- closed
- channel
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title 1
- 239000003814 drug Substances 0.000 claims description 34
- 229940079593 drug Drugs 0.000 claims description 18
- 230000001681 protective effect Effects 0.000 claims description 14
- 229920003023 plastic Polymers 0.000 claims description 8
- 239000003708 ampul Substances 0.000 claims description 7
- 239000004033 plastic Substances 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 5
- 238000007789 sealing Methods 0.000 claims description 2
- 239000000463 material Substances 0.000 description 12
- 239000011521 glass Substances 0.000 description 10
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000004743 Polypropylene Substances 0.000 description 3
- 229940126601 medicinal product Drugs 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- -1 polypropylene Polymers 0.000 description 3
- 229920001155 polypropylene Polymers 0.000 description 3
- 239000004677 Nylon Substances 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical class COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229920001727 cellulose butyrate Polymers 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- LVUUZDVGYJABOG-UHFFFAOYSA-N nitroso prop-2-enoate Chemical compound C=CC(=O)ON=O LVUUZDVGYJABOG-UHFFFAOYSA-N 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N31/00—Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroup; Apparatus specially adapted for such methods
- G01N31/22—Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroup; Apparatus specially adapted for such methods using chemical indicators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J45/00—Ion-exchange in which a complex or a chelate is formed; Use of material as complex or chelate forming ion-exchangers; Treatment of material for improving the complex or chelate forming ion-exchange properties
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G59/00—Polycondensates containing more than one epoxy group per molecule; Macromolecules obtained by polymerising compounds containing more than one epoxy group per molecule using curing agents or catalysts which react with the epoxy groups
- C08G59/18—Macromolecules obtained by polymerising compounds containing more than one epoxy group per molecule using curing agents or catalysts which react with the epoxy groups ; e.g. general methods of curing
- C08G59/40—Macromolecules obtained by polymerising compounds containing more than one epoxy group per molecule using curing agents or catalysts which react with the epoxy groups ; e.g. general methods of curing characterised by the curing agents used
- C08G59/62—Alcohols or phenols
- C08G59/621—Phenols
- C08G59/623—Aminophenols
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G59/00—Polycondensates containing more than one epoxy group per molecule; Macromolecules obtained by polymerising compounds containing more than one epoxy group per molecule using curing agents or catalysts which react with the epoxy groups
- C08G59/18—Macromolecules obtained by polymerising compounds containing more than one epoxy group per molecule using curing agents or catalysts which react with the epoxy groups ; e.g. general methods of curing
- C08G59/68—Macromolecules obtained by polymerising compounds containing more than one epoxy group per molecule using curing agents or catalysts which react with the epoxy groups ; e.g. general methods of curing characterised by the catalysts used
- C08G59/686—Macromolecules obtained by polymerising compounds containing more than one epoxy group per molecule using curing agents or catalysts which react with the epoxy groups ; e.g. general methods of curing characterised by the catalysts used containing nitrogen
-
- C—CHEMISTRY; METALLURGY
- C10—PETROLEUM, GAS OR COKE INDUSTRIES; TECHNICAL GASES CONTAINING CARBON MONOXIDE; FUELS; LUBRICANTS; PEAT
- C10M—LUBRICATING COMPOSITIONS; USE OF CHEMICAL SUBSTANCES EITHER ALONE OR AS LUBRICATING INGREDIENTS IN A LUBRICATING COMPOSITION
- C10M1/00—Liquid compositions essentially based on mineral lubricating oils or fatty oils; Their use as lubricants
- C10M1/08—Liquid compositions essentially based on mineral lubricating oils or fatty oils; Their use as lubricants with additives
-
- C—CHEMISTRY; METALLURGY
- C10—PETROLEUM, GAS OR COKE INDUSTRIES; TECHNICAL GASES CONTAINING CARBON MONOXIDE; FUELS; LUBRICANTS; PEAT
- C10M—LUBRICATING COMPOSITIONS; USE OF CHEMICAL SUBSTANCES EITHER ALONE OR AS LUBRICATING INGREDIENTS IN A LUBRICATING COMPOSITION
- C10M133/00—Lubricating compositions characterised by the additive being an organic non-macromolecular compound containing nitrogen
- C10M133/02—Lubricating compositions characterised by the additive being an organic non-macromolecular compound containing nitrogen having a carbon chain of less than 30 atoms
- C10M133/04—Amines, e.g. polyalkylene polyamines; Quaternary amines
- C10M133/12—Amines, e.g. polyalkylene polyamines; Quaternary amines having amino groups bound to a carbon atom of a six-membered aromatic ring
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Polymers & Plastics (AREA)
- Oncology (AREA)
- Analytical Chemistry (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Description
Sprøyteampulle for legemidler. Syringe ampoule for medicines.
Der kjennes til legemidler bestemte sprøyteampuller, i hvilke en legemiddelbeholder er avlukket med et i beholderen inn-, satt stempel, som bærer et rørformet forbindelsesstykke, der er innrettet til påsetting av en kanyle, og hvis hulhet gjennom stempelet står i forbindelse med legemid-derrommet bak dette. Syringe ampoules specific to drugs are known, in which a drug container is sealed off with a piston inserted into the container, which carries a tubular connecting piece, which is arranged for the attachment of a needle, and whose cavity through the piston is in connection with the drug compartment behind this.
De kjente sprøyteampuller av denne art er av glass, der tåler varmesterilisasjon og i fremragende grad er ugjennomtrenge-lige for vann. Imidlertid er det en i praksis ufravikelig betingelse for brukbarheten av slike sprøyter, at forbiindelsesstykket er innelukket lufttett i en beskyttelseskappe, hvori det kan holde seg sterilt og unngå å bli utsatt for støt- og trykkpåvirkninger ved hvilke stempelet beveges i legemiddelbeholderen, og væske eventuelt kan trenge ut av denne. The known syringe ampoules of this kind are made of glass, which can withstand heat sterilization and are impermeable to water to an outstanding degree. However, it is an invariable condition in practice for the usability of such syringes, that the pre-injection piece is enclosed airtight in a protective cover, in which it can remain sterile and avoid being exposed to impact and pressure effects by which the piston is moved in the medicine container, and liquid can possibly need out of this.
Til oppnåelse herav er de kjente sprøyter innrettet slik at beskyttelseskappen er dannet av en forlengelse av legemiddelbeholderens vegg ut over det sted hvor stempelet er anbragt, og at det således dannete forlengete rør utenfor forbindelsesstykkets ytterste ende er lukket. For å lette fjernelsen av denne forlengelse, når sprøyten skal benyttes, er der i glassrørets ytre overflate utformet en røret omslut-tende rille, i hvilken røret forholdsvis lett kan knekkes eller overfiles umiddelbart utenfor stempelet. Ved tilstedeværelsen av denne rille svekkes glasset dog i betydelig grad, og ved overfilingen eller knekkingen fremkommer der glassplinter og andre glasspartikler med den derav følgende ri-siko for at sprøyten forurenses før injeksjonen, likesom man risikerer under bru-ken av sprøyten å skjære fingrene på den skarpe, eventuelt ujevne bruddflate. To achieve this, the known syringes are designed so that the protective cap is formed by an extension of the wall of the medicine container beyond the place where the piston is placed, and that the extended tube thus formed outside the outermost end of the connecting piece is closed. To facilitate the removal of this extension, when the syringe is to be used, a groove surrounding the tube is formed in the outer surface of the glass tube, in which the tube can relatively easily be broken or filed immediately outside the piston. However, the presence of this groove weakens the glass to a considerable extent, and when it is over-filed or broken, glass splinters and other glass particles appear with the resulting risk of contaminating the syringe before the injection, as well as the risk of cutting your fingers while using the syringe. the sharp, possibly uneven fracture surface.
Stempelet, som i alminnelighet er av kautsjuk, som glir forholdsvis lett på glass-overflatan når det hviler med et passende trykk mot denne, kommer dog lett til å gli tregt og ujevnt eller til å sette seg fast når sammentrykningen av kautsjukmaterialet er for stort. The piston, which is generally made of rubber, which slides relatively easily on the glass surface when it rests with suitable pressure against it, will however easily slide slowly and unevenly or become stuck when the compression of the rubber material is too great.
Dette forhold inntrer især lett fordi stempelet av hensyn til gjennomføring av en kanal for legemiddelet er utformet som en ring, hvis radiale utstrekning er så li-ten at den kun er istand til å oppta varia-sjoner i beholderens diameter av størrel-sesordenen 0,1 mm uten en følelig forskjell i friksjonen mellom kautsjuken og glass-veggen. This condition occurs particularly easily because the piston, in order to pass through a channel for the drug, is designed as a ring, the radial extent of which is so small that it is only able to accommodate variations in the diameter of the container of the order of magnitude 0, 1 mm without a noticeable difference in the friction between the rubber and the glass wall.
Da toleransen på glassrør til beholderens fremstilling vanskelig kan bringes len-gere ned enn til ca. 0,3 mm, selv etter en kalibrering, vil der således være en betydelig forskjell i den letthet med hvilken stemplene beveger seg i beholderne, hvilket er en stor ulempe ved disse sprøyter. As the tolerance on glass tubes for the manufacture of the container can hardly be brought down further than approx. 0.3 mm, even after a calibration, there will thus be a significant difference in the ease with which the pistons move in the containers, which is a major disadvantage of these syringes.
Ennvidere foranlediger tilsmeltnlngen av beskyttelseskappen i slike ampuller en opphetning og utvidelse av luften i denne, slik at der etter avkjøling av den tilsmel-tede ampulle oppstår et undertrykk i beskyttelseshetten, hvilket kan medføre at ampulleinnholdet siver mellom beholder-vegg og stempel ut i beskyttelseshetten under lagring av ampullen. Furthermore, the melting of the protective cap in such ampoules causes a heating and expansion of the air in it, so that after cooling of the fused ampoule, a negative pressure occurs in the protective cap, which can cause the ampoule contents to leak between the container wall and the piston into the protective cap under storage of the ampoule.
Der finnes andre typer sprøyteampul-ler, i hvilke noen av de ovenstående mang-ler er avhjulpet, men hvor andre mindre heldige trekk i så fall er trådt i stedet. Således omtales i tysk patent nr. 1 071 899 en sprøyteampulle, hvorpå er montert en løs hette til beskyttelse av en forut montert inijeksjonsnål. I ampuller av denne type oppnåes beskyttelsen av legemidlet ved at der over dette er montert en tett gummi-membran, som under injeksjonen gjennom-bores av en forlengelse av den forut mon-terte injeksjonsnål, og beskyttelseshetten har 1 slike sprøyteampuller til oppgave å isolere injeksjonsnålen fra omgivelsene og ikke å beskytte innholdet i legemiddelbeholderen. I ampuller av sistnevnte art kan der selvfølgelig ikke være valgfrihet for så vidt angår iinjeksjonismålen, hvis mest hen-siktsmessige dimensjon kan variere fra pasient til pasient og forøvrig også kan være avhengig av applikasjonsstedet, hvilket er en betydelig mangel ved sistnevnte ampuller. There are other types of syringe ampoules, in which some of the above shortcomings have been remedied, but where other less fortunate features have been replaced. Thus, in German patent no. 1 071 899, a syringe is described, on which a loose cap is mounted to protect a previously mounted injection needle. In ampoules of this type, the protection of the medicine is achieved by a tight rubber membrane being mounted above this, which during the injection is pierced by an extension of the previously mounted injection needle, and the protective cap has the task of insulating the injection needle. from the environment and not to protect the contents of the medicine container. In ampoules of the latter type, there can of course be no freedom of choice as far as the injection target is concerned, the most appropriate dimension of which may vary from patient to patient and may also depend on the application site, which is a significant shortcoming of the latter ampoules.
Ifølge oppfinnelsen unngås disse ulem-per, og der tilveiebringes en sikker og ens-artet virkende sprøyte som lett kan gjøres ferdig for bruk. According to the invention, these disadvantages are avoided, and a safe and uniform-acting syringe is provided which can easily be finished for use.
Til dette formål kjennetegnes ifølge For this purpose, according to
oppfinnelsen en sprøyte av den innlednings-vis angitte type ved at den består av en i den ene ende lukket legemiddelbeholder med sylindrisk innervegg, og et i beholderens annen og åpne ende innsatt mot beholderveggen tettende med en kanal gjennomboret stempel, som avsperrer en i beholderen innesluttet væske, hvilket stempel i sin kanal bærer et utadrettet for-bindelsesrør innrettet til påsetting av en kanyle, og hvor den nevnte kanal er lukket mot legemiddelbeholderen med en eller flere ventiler som ikke åpner seg før stempelet presses inn, og i hvilken sprøyteam-pulle der er montert en lett avtagbar, i den ene ende lukket beskyttelseshetite, der med sin åpne ende omslutter den ytterste del av legemiddelbeholderens ytterside og tet-ter imot denne, og som omslutter forbln-delsesrøret til påsetting av en kanyle uten å berøre forbindelsesrøret, og at såvel lege-miiddelbeholderen som beskyttelseshetten er fremstilt av plastikmateriale. the invention a syringe of the type indicated at the outset in that it consists of a medicine container with a cylindrical inner wall closed at one end, and a piston pierced with a channel in the other and open end of the container inserted against the container wall, sealing with a channel, which shuts off a liquid, which piston in its channel carries an outward-facing connecting tube arranged for the attachment of a needle, and where said channel is closed to the drug container with one or more valves that do not open until the piston is pressed in, and in which spray team pool where an easily removable protective hood is fitted, closed at one end, which with its open end encloses the outermost part of the medication container and seals against it, and which encloses the connecting tube for attaching a needle without touching the connecting tube, and that both the medical device container and the protective cap are made of plastic material.
Legemiddelbeholderen fremstilles med en toleranse fra 0.01 til 0.07 mm med en indre diameter av ca. 10 mm, og hensikts-mesBig med en toleranse på 0.025 mm hvilket er ti ganger mindre enn hva som kan oppnås ved masseproduksjon av til-svarende gla&sbeholdere. De materialer f oi legemiddelbeholdere som er vel egnet foi å oppnå nevnte toleranser er visse typer a\ plastikk, av praktiske grunner gj ennomsik-tig plastik, blant hvilke polycartaonat er et av de foretrukne materialer, da beholdere laget av dette kan varmedestilleres, men andre typer plastik kan også anvendes, f. eks. polystyren, og særlig slike typer polystyren som plastiseres ved tilsetning av acrylnitrit, cellulose acetat, -nitrat eller -butyrat, methylmetacrylater eller deriva-ter av disse, og visse polyamider, som f. eks. klar nylon. The medicine container is produced with a tolerance of 0.01 to 0.07 mm with an inner diameter of approx. 10 mm, and suitable with a tolerance of 0.025 mm, which is ten times less than what can be achieved by mass production of corresponding glass containers. The materials for pharmaceutical containers that are well suited for achieving the aforementioned tolerances are certain types of plastic, for practical reasons transparent plastic, among which polycarbonate is one of the preferred materials, as containers made from this can be heat-distilled, but others types of plastic can also be used, e.g. polystyrene, and particularly those types of polystyrene which are plasticized by the addition of acryl nitrite, cellulose acetate, -nitrate or -butyrate, methyl methacrylates or derivatives thereof, and certain polyamides, such as e.g. clear nylon.
Nevnte materialer er særlig bemerkel-sesverdige for sin dimensjonale stabilitet ved fremstilling, hvis fremstillingen foregår under passende forhold, og det har videre vist seg at de har en fordelaktig lav frik-sjonsmotstand mot kautsjuk og lignende stempelmaterialer. Said materials are particularly noteworthy for their dimensional stability during manufacture, if the manufacture takes place under suitable conditions, and it has also been shown that they have an advantageously low frictional resistance against rubber and similar piston materials.
Ifølge oppfinnelsen er beskyttelseskappen likeledes utformet av et plastikmateriale, fortrinnsvis poiypropylen; slike materialer har ikke glassets skjørhet, og særlig poiypropylen har en for en sikker festing på legemiddelbeholderen passende elastisi-tet og friksjon mot legemiddelbeholderens ytterside, i særdeleshet når legemiddelbeholderen er av polykarbonat. Det er hensiktsmessig at beskyttelseshetten ved sin munning har en fremspringende krave eller ører, eller et svakt konisk riflet stykke til fingerhold, som kan lette avtagningen av hetten. Legemiddelbeholderen er mest hensktsmesslg svakt konisk på yttersiden i nærheten av dens åpning, hvorved påsetting og avtagning av hetten lettes. Hetten kan være sandblåst på innersiden nær munningen. According to the invention, the protective cover is likewise designed from a plastic material, preferably polypropylene; such materials do not have the fragility of glass, and polypropylene in particular has a suitable elasticity and friction against the outside of the medicine container for a secure attachment to the medicine container, in particular when the medicine container is made of polycarbonate. It is appropriate for the protective cap to have a protruding collar or ears at its mouth, or a slightly conical fluted piece for finger grip, which can facilitate the removal of the cap. The medicine container is preferably slightly conical on the outside near its opening, thereby facilitating the fitting and removal of the cap. The cap may be sandblasted on the inside near the mouth.
Forbindelsesstykket, som med sin ene ende er innsatt i stempelet, og hvis annen ende er utformet med en konus, som pas-ser til de vanlige holdere for injeksjons-nåler, kan likeledes være utformet av plastikmateriale, særlig nylon. The connecting piece, which at one end is inserted into the piston, and whose other end is designed with a cone, which fits the usual holders for injection needles, can likewise be designed from plastic material, in particular nylon.
Når den foreliggende sprøyteampulle brukes for disse formål, f. eks. for oppbevaring og innsprøytning av legemidler som i ferdig blandet tilstand opptrer som emul-sjoner eller suspensjoner, kan den ulempe When the present syringe is used for these purposes, e.g. for the storage and injection of medicinal products which, in a ready-mixed state, act as emulsions or suspensions, it can disadvantage
forekomme at hulrommet (20) i stempelet occur that the cavity (20) in the piston
eller forbindelsesstykkets kanal kan være or the connector's channel can be
helt eller delvis blokkert av emulgerte eller suspenderte komponenter av legemid-1 delet, eller legemiddelet kan bunnfelle an-i dre komponenter som vil bevirke blokker - ing, helt eller delvis, av nevnte hulrom. Når dette hender bør sprøyten i al-l minnelighet kastes, og en ny sprøyte må tilberedes og brukes, vilket vil forårsake bortkastet tid og legemidler. completely or partially blocked by emulsified or suspended components of the medicinal product, or the medicinal product may precipitate other components which will cause blocking, fully or partially, of said cavity. When this happens, the syringe should be amicably thrown away and a new syringe prepared and used, which will cause a waste of time and medicines.
I en hensiktsmessig utførelse av opp-' finnelsen unngås denne ulempe ved at In an appropriate embodiment of the invention, this disadvantage is avoided by
■ stempelet forsynes med en utløpsåpning ■— ■ the piston is provided with an outlet opening ■—
påvirket av ventildeler — fra legemiddelbeholderen til hulrommet i stempelet og forbindelsesstykket, og således til nålen, f. eks. oppnådd ved en eller flere elastiske ventiler som gir etter for presset av væsken når stempelet presses ned, men ikke tillater suspenderte partikler å passere når legemiddelet er lagret og kanskje rystet inne i legerniddelbeholderen. affected by valve parts — from the drug container to the cavity in the piston and connecting piece, and thus to the needle, e.g. achieved by one or more elastic valves which yield to the pressure of the liquid when the plunger is depressed, but do not allow suspended particles to pass when the drug is stored and perhaps shaken inside the medical device container.
Nevnte ventildeler og utløpet til hulrommet i stempelet og forbindelsessitykket bar følgelig den virkning at suspenderte og emulgerte partikler som har blitt utskilt eller bunnfelt i legemiddelet inne i beholderen ikke kan komme inn i hulrommet under oppbevaring og derfor ikke får noen an-ledning til å lagres i hulrommet. Said valve parts and the outlet to the cavity in the piston and the connecting piece consequently had the effect that suspended and emulsified particles which have been secreted or settled in the drug inside the container cannot enter the cavity during storage and therefore have no opportunity to be stored in the cavity.
Fig. 1 på tegningen viser i aksialt snitt en utførelse av en sprøyteampulle ifølge foreliggende oppfinnelse. 1 er legemiddelbeholderen som passende er sirkulær-sylindrisk, fremstillet for et forutbestemt tverrsnitt, tilpasset den øn-skede mengde av legemiddel og stempelets størrelse, og i den foreliggende utførelse på omkring 10 mm, med en toleranse som ikke overskrider 0.025 mm. I den ene ende er beholderen lukket med en bunn 7 som har form av en riflet plate som strekker seg utover beholderens ytre diameter og danner en trykkfot 8, fortrinnsvis avlang, oval eller tilnærmet rektangulær av form. Fig. 1 in the drawing shows in axial section an embodiment of a syringe ampoule according to the present invention. 1, the drug container is suitably circular-cylindrical, manufactured for a predetermined cross-section, adapted to the desired amount of drug and the size of the piston, and in the present embodiment of about 10 mm, with a tolerance not exceeding 0.025 mm. At one end, the container is closed with a bottom 7 which has the shape of a fluted plate which extends beyond the outer diameter of the container and forms a pressure foot 8, preferably oblong, oval or approximately rectangular in shape.
I den andre ende er legemiddelbeholderen åpen, og har ved sin munning 9 en svakt konisk overflate 10 på utsiden. At the other end, the medicine container is open, and has a slightly conical surface 10 at its mouth 9 on the outside.
I legemiddelbeholderen er der innsatt et ringformet stempel 2, som mest hensiktsmessig kan være av kautsjuk, og på sin ytterside kan ha riller 11 og mellom-liggende flenser 12. I det ringformete stempels indre hulrom er der innsatt et forbindelsesstykke 3, som på i og for seg kjent måte kan ha en ansats 13 og en flens 14 for å sikre fastholdelsen av stempelet og styring av forbindelsesstykket i forhold til dette. I sitt indre har forbindelsestyk-ket i en kanal 15, gjennom hvilken legemiddelbeholderen l's indre står i forbindelse med hulnålen, når denne er påsatt forbindelsesstykket. Ved dettes annen ende er der til dette sistnevnte formål utformet en konisk flate 16. Forbindelsesstykket 'kan dessuten være forsynt'med en flens 22, som selv kan tjene som finger - grep eller kan danne støtte og styring for en påsatt fingerbøyle. 5 betegner en beskyttelseshette, som avtas før påsetting av hulnålen. Forbindelsesstykket er i den på tegningen viste utførelse videre forsynt med fire støtter 23 som står i rett vinkel i forhold til hverandre og ender i flensene 17, idet de støter opp til den indre sylinder-flate av legemiddelbeholderen og således styrer bevegelsen av forbindelsesstykket når sprøyten er i bruk. 4 er en beskyttelseskappe av plastikmateriale, fortrinnsvis poiypropylen. Kappen er formet som et rør langt nok til å omslutte forbindelsesstykket, når stempelet 2 befinner seg i sin ytterstilling ved legemiddelbeholderens 1 munning 9, og kappen er satt inn over legemiddelbeholderens ytterste koniske del som vist. Kappen er ved den ene ende lukket med en bunn 18 og har ved sin annen åpne ende en flens eller ører 18 som tj ener til dels å styrke dens kant, dels å lette kappens påsetting og avtagning. In the medicine container, an annular piston 2 is inserted, which can most conveniently be made of rubber, and on its outer side can have grooves 11 and intermediate flanges 12. In the inner cavity of the annular piston, a connecting piece 3 is inserted, as in and known way can have a shoulder 13 and a flange 14 to ensure the retention of the piston and control of the connecting piece in relation to this. In its interior, the connecting piece has a channel 15, through which the inside of the drug container 1 is in contact with the hollow needle, when this is attached to the connecting piece. At its other end, a conical surface 16 is designed for this latter purpose. The connecting piece 'can also be provided' with a flange 22, which itself can serve as a finger grip or can form support and guidance for an attached finger brace. 5 denotes a protective cap, which is removed before attaching the hollow needle. In the embodiment shown in the drawing, the connecting piece is further provided with four supports 23 which stand at right angles to each other and end in the flanges 17, as they abut against the inner cylinder surface of the medicine container and thus control the movement of the connecting piece when the syringe is in use. 4 is a protective cover of plastic material, preferably polypropylene. The cap is shaped like a tube long enough to enclose the connecting piece, when the piston 2 is in its outermost position at the mouth 9 of the drug container 1, and the cap is inserted over the outermost conical part of the drug container as shown. The cap is closed at one end with a bottom 18 and has at its other open end a flange or ears 18 which serve partly to strengthen its edge, partly to facilitate the putting on and taking off of the cap.
Fig. 1 på tegningen viser en utførelse, hvor stempelets hulrom (20) er adskilt fra det indre av legemiddelbeholderen 1 ved en ventillukning 21 der som det vil sees av fig. Fig. 1 in the drawing shows an embodiment, where the piston's cavity (20) is separated from the interior of the drug container 1 by a valve closure 21 where, as will be seen from fig.
2 og 3 kan bestå av fire ventiler dannet av 2 and 3 may consist of four valves formed by
en korsformet utskjæring av stempelmate-rialet, eller av en enkelt ventil dannet av en delvis sirkulær utskjæring som vist i fig. 3. Det vil forståes at slike ventildeler kan formes på mange måter, slik at de, ved utnyttelse av stempelmaterialets elastiske egenskaper, er istand til å beholde passa-sjen til hulrommet 15 lukket eller i det vesentlige lukket til stempelet 2 er presset ned og ventildelene er elastisk presset bak-over ved presset av væsken. a cross-shaped cutout of the piston material, or of a single valve formed by a partially circular cutout as shown in fig. 3. It will be understood that such valve parts can be shaped in many ways, so that, by utilizing the elastic properties of the piston material, they are able to keep the passage to the cavity 15 closed or substantially closed until the piston 2 is pressed down and the valve parts is elastically pushed backwards by the pressure of the liquid.
Claims (1)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US82487277A | 1977-08-15 | 1977-08-15 | |
| US87317478A | 1978-01-30 | 1978-01-30 | |
| US87304078A | 1978-01-30 | 1978-01-30 | |
| US87304178A | 1978-01-30 | 1978-01-30 | |
| US05/903,292 US4138415A (en) | 1978-05-05 | 1978-05-05 | 1,4-Bis(aminoalkylamino)-anthraquinones and leuco derivatives thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO782756L NO782756L (en) | 1979-02-16 |
| NO148777B true NO148777B (en) | 1983-09-05 |
| NO148777C NO148777C (en) | 1984-01-25 |
Family
ID=27542240
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO782756A NO148777C (en) | 1977-08-15 | 1978-08-14 | ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE ANTHRAKINON DERIVATIVES |
| NO820290A NO150482C (en) | 1977-08-15 | 1982-02-01 | INTERMEDIATES FOR THE PREPARATION OF THERAPEUTIC ACTIVE ANTHRAKINON DERIVATIVES |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO820290A NO150482C (en) | 1977-08-15 | 1982-02-01 | INTERMEDIATES FOR THE PREPARATION OF THERAPEUTIC ACTIVE ANTHRAKINON DERIVATIVES |
Country Status (22)
| Country | Link |
|---|---|
| JP (1) | JPS6463556A (en) |
| AR (1) | AR225884A1 (en) |
| AT (1) | AT359484B (en) |
| AU (1) | AU527103B2 (en) |
| BE (1) | BE869688A (en) |
| CH (1) | CH644840A5 (en) |
| DD (1) | DD139256A5 (en) |
| DE (1) | DE2835661A1 (en) |
| DK (1) | DK158836C (en) |
| FI (1) | FI70882C (en) |
| FR (1) | FR2400504A1 (en) |
| GB (1) | GB2004293B (en) |
| GR (1) | GR74415B (en) |
| IE (1) | IE47253B1 (en) |
| IL (1) | IL55218A (en) |
| IT (1) | IT1107773B (en) |
| NL (1) | NL188981C (en) |
| NO (2) | NO148777C (en) |
| NZ (1) | NZ187989A (en) |
| PL (1) | PL122586B1 (en) |
| PT (1) | PT68420A (en) |
| SE (1) | SE445996B (en) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4275009A (en) * | 1979-05-29 | 1981-06-23 | American Cyanamid Company | 1-(Aminoalkylamino)-5,8-dihydroxy-4-substituted-anthraquinones |
| US4275010A (en) * | 1979-10-24 | 1981-06-23 | American Cyanamid Company | 5,8-Dihydroxy-1,4-bis(guanidinylamino)anthraquinones |
| US4296030A (en) * | 1980-04-09 | 1981-10-20 | American Cyanamid Company | Metal chelates of 1,4-bis(substituted-amino-5,8-dihydroxy-anthraquinones |
| US4278605A (en) * | 1980-06-30 | 1981-07-14 | American Cyanamid Company | Heteroalkylenebisanthraquinones |
| EP0052853A1 (en) * | 1980-11-24 | 1982-06-02 | Hoechst Aktiengesellschaft | Bis-aminomethyl-anthraquinone derivatives, process for their manufacture, compositions containing them and their use |
| EP0083683A1 (en) * | 1981-10-26 | 1983-07-20 | American Cyanamid Company | Method of preparing 1,4-bis(substituted-amino)-5,8-dihydroxyanthraquinones and pharmaceutical compositions containing them |
| ATE48942T1 (en) * | 1984-02-27 | 1990-01-15 | American Cyanamid Co | USE OF 1,4 BI-SUBSTITUTED ANTHRACHINONES FOR THE MANUFACTURE OF IMMUNOSUPPRESSIVES. |
| EP0182135A3 (en) * | 1984-11-19 | 1987-08-05 | American Cyanamid Company | Novel bis-(substituted amino) anthraquinones |
| US5436243A (en) * | 1993-11-17 | 1995-07-25 | Research Triangle Institute Duke University | Aminoanthraquinone derivatives to combat multidrug resistance |
| GB9815910D0 (en) * | 1998-07-21 | 1998-09-23 | Btg Int Ltd | Synthetic method |
| CA2550839A1 (en) * | 2003-12-23 | 2005-07-07 | Somanta Limited | Antharquinone compounds as anti cancer compounds |
| US8173621B2 (en) | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
| AR074897A1 (en) | 2008-12-23 | 2011-02-23 | Pharmasset Inc | NUCLEOSID PHOSPHORAMIDATES |
| AU2009329917B2 (en) | 2008-12-23 | 2016-03-31 | Gilead Pharmasset Llc | Nucleoside analogs |
| SG194404A1 (en) | 2008-12-23 | 2013-11-29 | Gilead Pharmasset Llc | Synthesis of purine nucleosides |
| PT2609923T (en) | 2010-03-31 | 2017-08-30 | Gilead Pharmasset Llc | Process for the crystallisation of (s)-isopropyl 2-(((s)-(perfluorophenoxy)(phenoxy)phosphoryl)amino)propanoate |
| DE102012203981A1 (en) * | 2012-03-14 | 2013-09-19 | Henkel Ag & Co. Kgaa | Agent for dyeing and / or delustering keratin-containing fibers containing novel 1,4-diaminoanthraquinone dyes |
| GB201214169D0 (en) | 2012-08-08 | 2012-09-19 | Biostatus Ltd | New compounds and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1422016A (en) * | 1962-10-29 | 1965-12-24 | Oreal | New anthraquinone dyes and their application to hair dye |
| GB1157506A (en) * | 1965-09-10 | 1969-07-09 | Ilford Ltd | Anthraquinone Dye Colour Couplers and their use in Colour Photographic Materials |
| US3700398A (en) * | 1970-07-27 | 1972-10-24 | Du Pont | Process for dyeing acid-modified nylon fibers |
| US3646072A (en) * | 1970-07-27 | 1972-02-29 | Du Pont | Turquoise biscationic anthraquinone dyes |
| US4051155A (en) * | 1975-12-15 | 1977-09-27 | Allied Chemical Corporation | Anthraquinone dyes |
-
1978
- 1978-07-19 SE SE7807987A patent/SE445996B/en not_active IP Right Cessation
- 1978-07-26 IL IL55218A patent/IL55218A/en active IP Right Grant
- 1978-07-27 NZ NZ187989A patent/NZ187989A/en unknown
- 1978-08-03 AR AR273195A patent/AR225884A1/en active
- 1978-08-07 GR GR56957A patent/GR74415B/el unknown
- 1978-08-09 AU AU38776/78A patent/AU527103B2/en not_active Expired
- 1978-08-09 FR FR7823503A patent/FR2400504A1/en active Granted
- 1978-08-11 BE BE78189842A patent/BE869688A/en not_active IP Right Cessation
- 1978-08-11 IE IE1636/78A patent/IE47253B1/en not_active IP Right Cessation
- 1978-08-14 CH CH862778A patent/CH644840A5/en not_active IP Right Cessation
- 1978-08-14 PT PT68420A patent/PT68420A/en unknown
- 1978-08-14 IT IT50730/78A patent/IT1107773B/en active
- 1978-08-14 DE DE19782835661 patent/DE2835661A1/en active Granted
- 1978-08-14 AT AT590678A patent/AT359484B/en not_active IP Right Cessation
- 1978-08-14 DK DK358678A patent/DK158836C/en not_active IP Right Cessation
- 1978-08-14 NO NO782756A patent/NO148777C/en unknown
- 1978-08-15 PL PL1978209065A patent/PL122586B1/en unknown
- 1978-08-15 FI FI782481A patent/FI70882C/en not_active IP Right Cessation
- 1978-08-15 GB GB7833365A patent/GB2004293B/en not_active Expired
- 1978-08-15 DD DD78207292A patent/DD139256A5/en unknown
- 1978-08-15 NL NLAANVRAGE7808475,A patent/NL188981C/en not_active IP Right Cessation
-
1982
- 1982-02-01 NO NO820290A patent/NO150482C/en unknown
-
1987
- 1987-12-16 JP JP62316353A patent/JPS6463556A/en active Granted
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO148777B (en) | ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE ANTHRAKINON DERIVATIVES | |
| US4235235A (en) | Syringe | |
| EP3679922B1 (en) | Syringe | |
| JP5651475B2 (en) | Dual chamber injection device with gas permeable membrane | |
| US4883473A (en) | Single use injection device | |
| US3826260A (en) | Vial and syringe combination | |
| NO309177B1 (en) | Device for dispensing a predetermined amount of liquid of a pharmaceutical product | |
| ES2896727T3 (en) | Injector | |
| US3739779A (en) | Hypodermic syringe and needle construction | |
| ES2633777T3 (en) | Pen needle assembly provided with biodegradable components | |
| US20180250474A1 (en) | Syringe Type Medication Delivery Device | |
| JP6411381B2 (en) | Injection needle with shield actuated valve | |
| US20180333534A1 (en) | An injection device with a removable cap | |
| KR102512255B1 (en) | A vessel for mixing and dispensing two ingredients | |
| DK162480B (en) | hypodermic syringe | |
| NO164880B (en) | DEVICE FOR THE MANAGEMENT OF TOXIC SUBSTANCES AND MEDICINES. | |
| JPH0444552B2 (en) | ||
| JPS62502386A (en) | Transfer device | |
| KR101513465B1 (en) | Safety filter for syringe | |
| NO133311B (en) | ||
| CA2991221A1 (en) | Single use delivery device prefilled with a reconstitutable agent | |
| NO162056B (en) | MEDICAL DELIVERY DEVICE. | |
| US20120083744A1 (en) | Packaging of Delivery Device for Aseptic Filling and Distribution | |
| MX2007000295A (en) | Syringe device having venting system. | |
| EP2879645A1 (en) | Dose counting device for coupling with a medical container |